Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ariel Hurtado

Anesthesiology Freedom, CA Medical Doctor

NPI 1255659181 CMS profile 969068

160 Green Valley Rd, Ste 101, Freedom, CA 95019

Open in the dashboard

General payments

$6,788

50 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ariel Hurtado of Freedom, CA is reported in the CMS Open Payments database as having received $6,788 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $347 6
2023 General $260 10
2022 General $214 6
2021 General $4,889 22
2020 General $957 5
2019 General $120 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ariel Hurtado
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Ariel Hurtado were reported at $0. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Ariel Hurtado Anesthesiology median Middle half National median
2019 $120 $72 $23–$151 $163
2020 $957 $36 $17–$120 $114
2021 $4,889 $49 $21–$135 $132
2022 $214 $52 $22–$144 $149
2023 $260 $53 $23–$143 $160
2024 $347 $55 $25–$150 $164
2025 $0 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AcelRx Pharmaceuticals, Inc. $5,535 15 payments
  2. Abbott Laboratories $532 15 payments
  3. Stryker Corporation $185 2 payments
  4. AbbVie, Inc. $175 11 payments
  5. Vertos Medical, Inc. $128 1 payment
  6. Painteq LLC $119 2 payments
  7. Gilead Sciences, Inc. $45 2 payments
  8. Avanos Medical $41 1 payment
  9. Allergan Inc. $27 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Honoraria $4,400 3 payments
  2. Food and Beverage $1,463 43 payments
  3. Consulting Fee $900 1 payment
  4. Education $25 3 payments
Products named General payments · program years 2019–2024
  1. DSUVIA $5,535 15 payments
  2. Proclaim IPG $298 8 payments
  3. MILD DEVICE KIT Instruments $185 2 payments
  4. PROCLAIM $154 4 payments
  5. mild Device Kit Orthopedic $128 1 payment
  6. PAINTEQ $119 2 payments
  7. BOTOX $117 6 payments
  8. Proclaim DRG IPG $48 2 payments
  9. UBRELVY $44 2 payments
  10. ON-Q* PUMP AND ACCESSORIES $41 1 payment
  11. Other $143 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$319,914

Of which drugs: $48,249

Medicare patients

317

Average age 75

Services billed

11,355

179 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Diabetes 38%
Ischemic heart disease 26%
Depression 26%
Chronic kidney disease 23%
Osteoporosis 22%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 16 8,800 $43,838
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 134 483 $2,636
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 16 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $22
$22 — 8,800
QULIPTA
  • AbbVie, Inc. $12
$12 — —
UBRELVY
  • AbbVie, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record